111 related articles for article (PubMed ID: 17637536)
1. [How to select the treatment options in prostate cancer].
Karasawa K; Chang TC; Kuga G; Hanyu N; Yoshida D
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1006-10. PubMed ID: 17637536
[TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
3. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
4. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
[TBL] [Abstract][Full Text] [Related]
5. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
6. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
7. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
8. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
[TBL] [Abstract][Full Text] [Related]
10. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
11. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
12. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
[TBL] [Abstract][Full Text] [Related]
13. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: the relationship between dose-volume histogram parameters and the occurrence rate.
Okamoto M; Ishikawa H; Ebara T; Kato H; Tamaki T; Akimoto T; Ito K; Miyakubo M; Yamamoto T; Suzuki K; Takahashi T; Nakano T
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):e211-7. PubMed ID: 21620579
[TBL] [Abstract][Full Text] [Related]
14. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
15. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors.
Martinez A; Gonzalez J; Spencer W; Gustafson G; Kestin L; Kearney D; Vicini FA
J Urol; 2003 Mar; 169(3):974-9; discussion 979-80. PubMed ID: 12576825
[TBL] [Abstract][Full Text] [Related]
16. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
Akimoto T; Katoh H; Kitamoto Y; Tamaki T; Harada K; Shirai K; Nakano T
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):364-70. PubMed ID: 16690428
[TBL] [Abstract][Full Text] [Related]
17. Dose constraint for minimizing grade 2 rectal bleeding following brachytherapy combined with external beam radiotherapy for localized prostate cancer: rectal dose-volume histogram analysis of 457 patients.
Shiraishi Y; Yorozu A; Ohashi T; Toya K; Seki S; Yoshida K; Kaneda T; Saito S; Nishiyama T; Hanada T; Shigematsu N
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e127-33. PubMed ID: 21398047
[TBL] [Abstract][Full Text] [Related]
18. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
[TBL] [Abstract][Full Text] [Related]
19. [Advances in brachytherapy--focusing on the permanent implant for early prostate carcinoma].
Hirokawa Y
Gan To Kagaku Ryoho; 2003 Dec; 30(13):2056-61. PubMed ID: 14712765
[TBL] [Abstract][Full Text] [Related]
20. [Review on the effectiveness of prostate cancer brachytherapy].
Inciūra A; Jarusevicus L; Vaiciūnas K; Juozaityte E
Medicina (Kaunas); 2009; 45(8):660-71. PubMed ID: 19773626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]